IL9 and systemic sclerosis: Furthermore, bleomycin-induced SSc mice treated with an anti-IL-9 antibody exhibited reduced scleroderma, less body weight loss, limited collagen deposition in the skin, and a decreased expression of Acta2, Col1a1, Col1a2, and MMP-2 (16).